The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Drug Stocks Hit By Clinton Price-Gouging Tweet

Tue, 22nd Sep 2015 07:38

LONDON (Alliance News) - London-listed stocks opened largely lower Tuesday, with the focus on individual stocks, as pharmaceutical company shares were sold after US presidential candidate Hillary Clinton tweeted about "price gouging" in the specialty drug market.

On her official twitter account Monday, Clinton cited a New York Times article which said the price of the Daraprim drug, which treats a life-threatening parasitic infection, soared to USD750 a tablet from USD13.50 a tablet overnight.

Clinton, the frontrunner for the Democratic nomination, tweeted "price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on".

Shares in US pharmaceutical companies dropped on Monday following the tweet and London-listed pharmaceuticals were following suit early Tuesday. AstraZeneca was down 2.2%, Shire down 2.7% and GlaxoSmithKline down 1.8%.

Elsewhere, miners were again amongst the worst performers in the blue-chip index after downgrades from Credit Suisse. Antofagasta was down 3.5% after the bank cut it to Underperform from Neutral, while Anglo American was down 3.5% after being cut to Neutral from Outperform.

In the FTSE 250, IG Group was the best performer, up 3.8% after it said its revenue increased substantially in the first quarter against a weak comparative, but said the volatile market conditions make it difficult to predict an outcome for the full year.

The spread betting and contracts-for-difference company, which gives retail traders access to financial markets, said it is trading in line with its expectations at present, with revenue in the first quarter to the end of August up 24% to GBP106.0 million, though it noted the same period last year was "particularly subdued".

Card Factory was another strong performer, up 1.1%, after it said it made a profit in the first half of its financial year, having suffered a loss the year before, as revenue rose and it declared payment of a special dividend.

The card and gifts retailer said that it made a pretax profit of GBP24 million in the six months ended July 31, after it suffered a GBP7.9 million pretax loss in the same period the prior year, boosted in the current year due to a significant reduction in net financing expenses to GBP2.1 million from GBP11.2 million.

Breakdown cover and roadside assistance company AA was the heaviest faller in the FTSE 250, down 5.9%. The company said its trading profit fell in the first half, though it said it is trading in line for the full year and said it will pay an interim dividend, its first since listing in mid-2014.

AA said its trading earnings before interest, taxation, depreciation and amortisation in the half to the end of July was down to GBP199.2 million from GBP211.8 million a year earlier, blamed by the company on the early phasing of marketing spend, the roll-out of diagnostic technology, a run-off of a former credit card account in its financial services division, the weak euro in Ireland, and higher operating costs.

AG Barr reported a fall in profit in the first half of its financial year, as the Scottish soft drinks company said revenue was hit by challenging market conditions, poor weather and a tough comparative period last year.

AG Barr, which makes brands including Irn-Bru and Rubicon, reported a fall in pretax profit in the six months ended July 25 to GBP16.9 million from GBP19.0 million in the first half of the prior year, as revenue declined to GBP130.3 million from GBP135.7 million. The company traded down 4.9%.

Just after the open, the blue-chip FTSE 100 index traded down 0.6% at 6,074.43, the FTSE 250 was down 0.4% at 16,820.56, while London's junior market AIM traded lower, with the AIM All-Share index down 0.3% at 737.83.

In Europe, the CAC 40 index in Paris was down 0.4% and the DAX 30 in Frankfurt traded down 0.1%.

Stocks in Asia were higher, with the Hang Seng index up 1.1% and the Shanghai Composite up 0.9%. The Japanese market remains closed for holiday until Thursday.

Still ahead in the economic calendar, UK public sector net borrowing is at 0930 BST, before the Confederation of British Industry's Industrial Trends Survey at 1100 BST. In the afternoon, the US Redbook index is at 1355 BST just before the housing price index at 1400 BST.

Key for London's listed supermarkets Tuesday, Kantar Worldpanel Supermarket market share data for the 12 weeks to September 13 will be released at 0930 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.